Abstract:Introduction: The SPiReL phase II clinical trial evaluated combination immunotherapy with an immunogenic vaccine formulation to the tumor antigen survivin comprised of maveropepimut-S (MVP-S), pembrolizumab and cyclophosphamide in survivin-expressing relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL). The efficacy of this survivin-directed T cell educating therapy may be influenced by the survivin antigen burden in the DLBCL. To further explore this potential relationship, we evaluated the heterogeneity of tumor survivin expression in the SPiReL study cohort and its associations with established clinical-pathological DLBLC variables. Methods: Survivin immunohistochemistry (IHC) was performed at NeoGenomics Laboratories (Aliso Viejo, California, USA) on formalin fixed paraffin embedded (FFPE) tumor slides from diagnostic biopsies obtained at trial screening. Inclusion criteria stipulated >10% of tumor cells expressing survivin by IHC. Semi-quantitative survivin expression metrics, as determined by pathologist assessment, included: total percentage of survivin-positive cells; intensity of survivin staining scored as 0 = None, 1+ = Weak, 2+ = Moderate, 3+ = Strong; and H-score, a linear weighted average (% positive cells x staining intensity level). Radiologic tumor burden was measured at up to 4 time points during the trial by computed tomography (CT). Other pathology (e.g. cell of origin) and laboratory biomarkers (e.g. lactate dehydrogenase, LDH) were extracted from clinical results. Results: The mean and median percentage of survivin-positive tumor cells for all enrolled participants (n= 25) was 91% and 99%, respectively. At the per participant level, the range of survivin expression was 50-100% of the cellular content. The heterogeneity of survivin expression intensity among participants is shown in Figure 1. All participants had some proportion of biopsied cells expressing strong (3+) intensity survivin (range: 5-100% of cells, mean: 30% while only 52% of tumors contained non-survivin expressing (0) cells, ranging from 0% to 50% (mean: 9%) Greater proportions of cells that expressed moderate (2+) and/or strong (3+) survivin significantly correlated with clinical and biological markers of aggressive DLBCL. Non-GCB tumours (11/25) showed greater H-scores compared to GCB tumours (212 vs 167, p = 0.0287). Non-GCB tumours contained greater proportions of strong intensity (3+) survivin cells compared to GCB tumours (44% vs 25%, p= 0.045). In addition, participants with LDH above the upper limit of normal at screening (52%, 13/25) had a greater mean proportion of cells expressing moderate and strong intensity survivin (proportion of 2+ and 3+ combined) (72% vs 54%, p = 0.0447) and a lower mean proportion of weak survivin intensity (1+) cells (p = 0.0374) compared to those with normal LDH. A relationship between total tumor area at baseline and survivin intensity levels was explored. Higher proportions of cells expressing weak intensity (1+) survivin were associated with smaller total tumour area at baseline (p=0.0201). In contrast, higher combined proportions of moderate (2+) and high (3+) intensity survivin was associated with larger total tumour area at baseline (p=0.0285). The significant association with the 2+/3+ intensity of survivin with LDH, cell of origin and tumour burden may suggest a mechanistic threshold in DLBCL pathobiology that drives aggressive clinical behavior. Discussion: Here we demonstrate substantial heterogeneity of survivin protein expression in baseline tumour biopsies of R/R DLBCL patients. Given our findings, it may be of clinical and pathobiological significance to assess both the proportion of survivin-expressing cells as well as the intensity of survivin expression. As the known functions of survivin include protection from apoptosis and cell-cycle progression, the associations demonstrated here support the relevance of survivin and in particular high intensity (2+, 3+) survivin as a biomarker linked with aggressive R/R DLBCL features. These results further support the targeting of survivin pathways in interventional trials and development of validated clinical laboratory survivin assays. Further analysis by multiplex immunofluorescence is in progress to further explore how 2+/3+ vs. 0 host immune cells may also influence survivin immunogenicity and clinical response post-MVP-S immunotherapy.

Heat shock proteins and survivin: relationship and effects on proliferation index of retinoblastoma cells.

The role of PAX6 and its downstream gene on differentiation of human retinoblastoma cells

Expression of Multidrug-Resistance Associated Proteins in Human Retinoblastoma Treated by Primary Enucleation

P38 Mitogen-Activated Protein Kinase Protects Against Retinoblastoma Through Regulating USP22/SIRT1/SOST Axis

Expression of the P53, Bcl - 2 and PCNA in Retinoblastoma

Expression Of Emmprin, Mmps And Timp2 In Retinoblastoma And Normal Retinal Tissue

Expression and clinical significance of brain derived neurotrophic factor in retinoblastoma

Ubiquitin specific peptidase 33 promotes cell proliferation and reduces apoptosis through regulation of the SP1/PI3K/AKT pathway in retinoblastoma

The Rb1 Gene Inhibits the Viability of Retinoblastoma Cells by Regulating Homologous Recombination

CTSB Nuclear Translocation Facilitates DNA Damage and Lysosomal Stress to Promote Retinoblastoma Cell Death

[Upregulation of Survivin in Non-Small Cell Lung Cancer and Its Clinicopathological Correlation with P53 and Bcl-2].

Survivin Expression and Its Relation with Proliferation, Apoptosis, and Angiogenesis in Brain Gliomas

Itraq-Based Quantitative Proteomic Analysis and Bioinformatics Study of Proteins in Retinoblastoma.

Clinicopathologic Significances of Nuclear Expression of Nuclear Factor- B Transcription Factors in Retinoblastoma

Thrombospondin-1 Might Be a Therapeutic Target to Suppress RB Cells by Regulating the DNA Double-Strand Breaks Repair

Intensity of Survivin Expression Correlates with Clinical and Biological Markers of Aggressive R/R DLBCL

Analysis of Aqueous Humor Concentrations of Cytokines in Retinoblastoma.

Expression of p21WAF1/CIP1 in retinoblastoma and its significance

Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway

Clinical treatment and prognostic observation for different pathological infiltrations in 537 patients with unilateral retinoblastoma.

Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis